Researchers from the National Cancer Research Center (CNIO) have discovered more than 40 genes that define the degree of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. This study is relevant because it also explains why a drug also described in the CNIO is incorporated and selectively attacks tumor cells of melanoma. Melanoma is today one of the most metastatic and worst known cancers.
The finding, which is published in Cancer Cell, will help determine unique aspects of melanoma that may contribute to determining the risk of developing metastases in patients with this disease.